Switch theme
Sign up to access all valuation multiples
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
2017
432
LTM Revenue $136M
LTM EBITDA -$97.9M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Everest Medicines has a last 12-month revenue of $136M and a last 12-month EBITDA of -$97.9M.
In the most recent fiscal year, Everest Medicines achieved revenue of $16.2M and an EBITDA of -$95.8M.
Everest Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Everest Medicines valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.6M | $16.2M | XXX | XXX | XXX |
| Gross Profit | $4K | $1.0M | XXX | XXX | XXX |
| Gross Margin | 0% | 6% | XXX | XXX | XXX |
| EBITDA | -$25.6M | -$95.8M | XXX | XXX | XXX |
| EBITDA Margin | -1555% | -591% | XXX | XXX | XXX |
| Net Profit | -$130M | -$31.8M | XXX | XXX | XXX |
| Net Margin | -7886% | -196% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Everest Medicines's stock price is HKD 50 (or $6).
Everest Medicines has current market cap of HKD 16.3B (or $2.1B), and EV of HKD 15.2B (or $2.0B).
See Everest Medicines trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.1B | XXX | XXX | XXX | XXX | $-0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Everest Medicines has market cap of $2.1B and EV of $2.0B.
Everest Medicines's trades at 15.4x LTM EV/Revenue multiple, and -21.4x LTM EBITDA.
Analysts estimate Everest Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Everest Medicines and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 120.7x | XXX | XXX | XXX |
| EV/EBITDA | -20.4x | XXX | XXX | XXX |
| P/E | -19.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -14.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEverest Medicines's NTM/LTM revenue growth is 85%
Everest Medicines's revenue per employee for the last fiscal year averaged $37K, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Everest Medicines's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Everest Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Everest Medicines and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 884% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -591% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 274% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -506% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $37K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 184% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 131% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 429% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 733% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Everest Medicines acquired XXX companies to date.
Last acquisition by Everest Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . Everest Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Everest Medicines founded? | Everest Medicines was founded in 2017. |
| Where is Everest Medicines headquartered? | Everest Medicines is headquartered in Hong Kong. |
| How many employees does Everest Medicines have? | As of today, Everest Medicines has 432 employees. |
| Who is the CEO of Everest Medicines? | Everest Medicines's CEO is Mr. Yongqing Luo. |
| Is Everest Medicines publicy listed? | Yes, Everest Medicines is a public company listed on HKG. |
| What is the stock symbol of Everest Medicines? | Everest Medicines trades under 01952 ticker. |
| When did Everest Medicines go public? | Everest Medicines went public in 2020. |
| Who are competitors of Everest Medicines? | Similar companies to Everest Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Everest Medicines? | Everest Medicines's current market cap is $2.1B |
| What is the current revenue of Everest Medicines? | Everest Medicines's last 12-month revenue is $136M. |
| What is the current EBITDA of Everest Medicines? | Everest Medicines's last 12-month EBITDA is -$97.9M. |
| What is the current EV/Revenue multiple of Everest Medicines? | Current revenue multiple of Everest Medicines is 15.4x. |
| What is the current EV/EBITDA multiple of Everest Medicines? | Current EBITDA multiple of Everest Medicines is -21.4x. |
| What is the current revenue growth of Everest Medicines? | Everest Medicines revenue growth between 2023 and 2024 was 884%. |
| Is Everest Medicines profitable? | Yes, Everest Medicines is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
